PCIA
HRTX icon

Prime Capital Investment Advisors’s Heron Therapeutics HRTX Stock Holding History

Prime Capital Investment Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,000
Closed -$30K – 473
2020
Q3 		$30K Buy
2,000
+950
+90% +$14.8K ﹤0.01% 354
2020
Q2 		$15K Buy
1,050
+465
+79% +$7.64K ﹤0.01% 396
2020
Q1 		$7K Buy
585
+100
+21% +$1.88K ﹤0.01% 417
2019
Q4 		$11K Buy
485
+110
+29% +$2.43K ﹤0.01% 484
2019
Q3 		$7K Buy
+375
New +$6.9K ﹤0.01% 566

Other funds holding HRTX

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Prime Capital Investment Advisors's HRTX Position: Q4 2020 in Review

Prime Capital Investment Advisors sold out of Heron Therapeutics (HRTX) in Q4 2020, closing a stake of 2,000 shares — an estimated $30K sold.

Prime Capital Investment Advisors first reported a position in HRTX in Q3 2019 and held it in 5 quarters. The position peaked at $30K in Q3 2020. 189 funds tracked by Wall St. Rank hold HRTX as of Q4 2020.

  • Prime Capital Investment Advisors reported no remaining Heron Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Prime Capital Investment Advisors sold 2,000 Heron Therapeutics shares in Q4 2020, an estimated $30K.
  • Prime Capital Investment Advisors first reported a position in Heron Therapeutics in Q3 2019 and held it in 5 quarters.
  • Prime Capital Investment Advisors's Heron Therapeutics position peaked at $30K in Q3 2020.
  • 189 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2020.

Based on Prime Capital Investment Advisors's 13F filing for Q4 2020, filed 3 Feb 2021.